Hollister Biosciences Inc. Subsidiary AlphaMind Brands Inc. Plans to Launch Initial Medicinal Mushroom Based Product Line

VANCOUVER, BC, June 4, 2020 /CNW/ – Hollister Biosciences Inc. (CSE: HOLL) (OTCPINK: HSTRF) (Frankfurt: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce that the Company’s 100% owned subsidiary, AlphaMind Brands Inc. (“AlphaMind”) plans to launch medicinal mushroom based capsule and powder product lines.Continue reading “Hollister Biosciences Inc. Subsidiary AlphaMind Brands Inc. Plans to Launch Initial Medicinal Mushroom Based Product Line”

FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis

TORONTO, June 3, 2020 /CNW/ – FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA)  to treat COVID-19, the disease caused by the SARS-CoV-2 virus.Continue reading “FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis”